Limited incremental value of growth differentiation factor 15 in the initial evaluation of low and intermediate risk acute chest pain patients
In patients with acute chest pain but without acute myocardial infarction, GDF-15 did not substantially improve the identification of obstructive CAD or need for revascularization within 30 days and 12 months. Our findings question the clinical usefulness of GDF-15 for prognostication of low-risk patients with acute chest pain.
Authors
- Kristin M. Aakre (ORCID: https://orcid.org/0000-0002-7340-6736)
- Øyvind Skadberg (ORCID: https://orcid.org/0000-0002-5525-2016)
- Iman Karaji (ORCID: https://orcid.org/0000-0003-2719-6106)
- Gard M. S. Myrmel (ORCID: https://orcid.org/0000-0003-4885-1085)
- Paul Collinson (ORCID: https://orcid.org/0000-0002-7000-5996)
- Kjell Vikenes
- Rune Bjørneklett (ORCID: https://orcid.org/0000-0001-6637-5743)
- Ole‐Thomas Steiro (ORCID: https://orcid.org/0000-0003-2520-9436)
- Jørund Langørgen (ORCID: https://orcid.org/0000-0003-3037-054X)
- Torbjørn Omland (ORCID: https://orcid.org/0000-0002-6452-0369)
- Hilde L Tjora (ORCID: https://orcid.org/0000-0003-2577-5497)
- Eva Ringdal Pedersen (ORCID: https://orcid.org/0000-0002-2545-1866)
- Vernon Bonarjee (ORCID: https://orcid.org/0000-0001-8149-0678)
- Terje H. Larsen (ORCID: https://orcid.org/0000-0003-4066-9190)
- Øistein R Mjelva
Institutions
- St George's, University of London (GB)
- Stavanger University Hospital (NO)
- Haukeland University Hospital (NO)
- City St George's, University of London (GB)
- University of Bergen (NO)
Publication Details
- Journal
- Clinical Biochemistry
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1016/j.clinbiochem.2025.110926
- Primary Topic
- GDF15 and Related Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00